Skip to content



Leveraging Patient Engagement Through Collaboration for Improved Global Health Outcomes in Sarcoma, Denisse Evans, MSc, Sara Rothschild, MPH, Carol Tordella, and Matías Chacón, MD, American Society of Clinical Oncology Educational Book
Volume 44, Number 3.

Immunotherapy in Sarcoma: Current Data and Promising Strategies, Georgina E. Wood, MD, PhD, Christian Meyer, MD, Florent Petitprez, PhD, and Sandra P. D’Angelo, MD, American Society of Clinical Oncology Educational Book, Volume 44, Number 3.

Sarcoma incidence worldwide: regional differences in histology and molecular subtypes, Lee MJ, Chen TW, Curr Opin Oncol. 2024 Apr 26. doi: 10.1097/CCO.0000000000001046. Epub ahead of print. PMID: 38726812.

What Is a Sarcoma ‘Specialist Center’? Multidisciplinary Research Finds an Answer, Wilson R, Reinke D, van Oortmerssen G, Gonzato O, Ott G, Raut CP, Guadagnolo BA, Haas RLM, Trent J, Jones R, et al. What Is a Sarcoma ‘Specialist Center’? Multidisciplinary Research Finds an Answer. Cancers. 2024; 16(10):1857.

Surgical resection of retroperitoneal sarcoma, updated 1/2/2024, William Tseng, MD.

Making the Decision to Enroll in a Clinical Trial – Chondrosarcoma Foundation, 2024.

Best Overall Response-associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE, Liu J, Moura DS, Jones RL, Aggarwal A, Philip EJ, Wagner AJ, Wright J, Martín-Broto J, Tap WD, Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3936. Epub ahead of print. PMID: 38536068.


Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors, Xu Y, Shi F, Zhang Y, Yin M, Han X, Feng J, Wang G. x Int J Cancer. 2024 Jan 15;154(2):226-240. doi: 10.1002/ijc.34694. Epub 2023 Aug 19. PMID: 37596989.

Rapid Classification of Sarcomas Using Methylation Fingerprint: A Pilot Study, Iluz A, Maoz M, Lavi N, Charbit H, Or O, Olshinka N, Demma JA, Adileh M, Wygoda M, Blumenfeld P, Gliner-Ron M, Azraq Y, Moss J, Peretz T, Eden A, Zick A, Lavon I., Cancers (Basel). 2023 Aug 18;15(16):4168. doi: 10.3390/cancers15164168. PMID: 37627196; PMCID: PMC10453223.

The protemic landscape. of soft tissue sarcoma, Burns, J., Wilding, C.P., Krasny, L. et al., Nat Commun 14, 3834 (2023).

New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas, Gyuhee Seong, Sandra P. D’Angelo, Front. Oncol., 13 March 2023, Sec. Molecular and Cellular Oncology
Volume 13 – 2023 |

NCCN Information for all sarcoma subtypes:
NCCN Patient Guidelines for Soft Tissue Sarcoma
NCCN Guidelines for Bone Sarcoma

Non-coding RNAs in metabolic reprogramming of bone and soft tissue sarcoma: Fundamental mechanism and clinical implication, Huan-Huan Chen , Peng-Hui Hao, Fang-Yuan Zhang, Tie-Ning Zhang, Science Direct, Elsevier, Biomedicine & Pharmacotherapy, Vol. 160, April 2023

Prognostic impact of circulating tumor cells in patients with soft-tissue sarcomas: a prospective study, Julie Blanchi, Audrey Laroche-Clary, François Le Loarer, Benjamin Bonhomme, Antoine Italiano, Cancer Communications, February 3, 2023, (DOI: 10.1002/cac2.12389)

High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations
Josephine K. Dermawan, Sarah Chiang, Martee L. Hensley, William D. Tap, Cristina R. Antonescu, Science Direct, Elsevier, Modern Pathology, Vol. 36, Issue 5, originally published January 23, 2023 (DOI:


Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas, William G. J. Kerrison, Alexander T. J. Lee, Khin Thway, Robin L. Jones, Paul H. Huang, Emmy D. G. Fleuren, Biomedicines, February 28, 2023 (doi: 10.3390/biomedicines10030573)